- Home
- CRTO vs IMCR Comparison
CRTO vs IMCR Comparison
Compare CRTO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- IMCR
- Stock Information
- Founded
- CRTO 2005
- IMCR 2008
- Country
- CRTO France
- IMCR United Kingdom
- Employees
- CRTO N/A
- IMCR N/A
- Industry
- CRTO Advertising
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRTO Consumer Discretionary
- IMCR Health Care
- Exchange
- CRTO Nasdaq
- IMCR Nasdaq
- Market Cap
- CRTO 1.4B
- IMCR 1.5B
- IPO Year
- CRTO 2013
- IMCR 2021
- Fundamental
- Price
- CRTO $25.00
- IMCR $32.80
- Analyst Decision
- CRTO Buy
- IMCR Buy
- Analyst Count
- CRTO 11
- IMCR 10
- Target Price
- CRTO $44.70
- IMCR $58.13
- AVG Volume (30 Days)
- CRTO 453.0K
- IMCR 444.9K
- Earning Date
- CRTO 07-31-2025
- IMCR 08-07-2025
- Dividend Yield
- CRTO N/A
- IMCR N/A
- EPS Growth
- CRTO 107.32
- IMCR N/A
- EPS
- CRTO 2.44
- IMCR N/A
- Revenue
- CRTO $1,934,668,000.00
- IMCR $333,581,000.00
- Revenue This Year
- CRTO N/A
- IMCR $26.82
- Revenue Next Year
- CRTO $1.96
- IMCR $8.15
- P/E Ratio
- CRTO $10.19
- IMCR N/A
- Revenue Growth
- CRTO N/A
- IMCR 25.75
- 52 Week Low
- CRTO $23.24
- IMCR $23.15
- 52 Week High
- CRTO $49.93
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- CRTO 47.05
- IMCR 51.47
- Support Level
- CRTO $23.70
- IMCR $30.76
- Resistance Level
- CRTO $24.82
- IMCR $33.95
- Average True Range (ATR)
- CRTO 0.80
- IMCR 1.39
- MACD
- CRTO 0.24
- IMCR -0.15
- Stochastic Oscillator
- CRTO 75.00
- IMCR 43.05
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.